Education Qualifications: MBBS, MRCP (UK), GradDip in Healthcare Management and Leadership (SMU)
Prof Lim graduated from the National University of Singapore and subsequently obtained his membership with the Royal College of Physician (UK). He received specialist training in medical oncology at the National Cancer Centre Singapore and further training in lymphoid malignancies at the University of Southern California.
Prof Lim is an esteemed clinician leader. As the former Deputy CEO (Clinical), NCCS, and Vice-Chair (Clinical Services), ONCO ACP, he was responsible for overseeing clinical strategy, and professional and clinical quality. He was also instrumental in supporting CEO, NCCS, in planning and facilitating the smooth transition of clinical services to the new NCCS building. He developed new models of care and established new services, such as geriatric oncology, cancer genetics and molecular tumour boards, to improve the delivery of patient-centred cancer care. Prof Lim also spearheaded the development of integrated cancer service lines, bringing together all cancer service providers across the cluster to ensure a seamless patient care journey, defined standards and accountability, as well as established collaborative databases.
Prof Lim held numerous clinical and research leadership roles and is an internationally renowned key opinion leader with an exemplary clinical and research track record in the field of lymphoma. He is the recipient of the Tanoto Foundation Professorship in Medical Oncology and is involved in multiple wide-ranging collaborations with local and international institutions that have led to many successful research and academic endeavours.
Prof Lim’s research focus is on lymphoid malignancies; in particular T and NK/T cell lymphomas, that occur more frequently in Asia. He is the co-founder of the Asian Lymphoma Study Group, which includes academic medical centers across Asia. Currently, Professor Lim is also the lead investigator of a translational and clinical Research (TCR) flagship programme funded by NMRC (National Lymphoma Translational Research Program: From Genomics to Therapeutics). His team now leads the blood cancer (T cell lymphoma) genomics project at the International Cancer Genomics Consortium. His research efforts won him the 3rd Kobayashi Foundation Award in May 2014 in Taipei. Previously, he was also awarded SingHealth Distinguished Young Leader Award in 2011. In 2015, he is also conferred the title of Tanoto Professorship in Lymphoma Research.
Professional Appointments and Committee Memberships:
- Deputy Group Chief Executive Officer (Research & Education), SingHealth
- Senior Consultant, SingHealth Duke-NUS Blood Cancer Centre
- Chairman, SingHealth Central Institutional Review Board
Awards:
- Tanoto Professorship in Lymphoma research (2015 – present)
- 3rd Kobayashi Foundation Award for Research Excellence (2014)
- Outstanding faculty for Advocacy Award (Practice Course) Class 2014, Duke-NUS
- SingHealth Distinguished Young Leader Award (2011)
- Dean’s Excellence in Teaching Award 2008/2009
- Excellent Service Award: STAR 2007
Leadership positions / roles in Education:
- Chair, Medical Oncology Residency Advisory Committee
Research Interests: Lymphoid malignancies; in particular T and NK/T cell lymphomas
Selected Publications:
Li ST, Yuen J, Zhou K, Binte Ishak ND, Chen Y, Met-Domestici M, Chan SH, Tan YP, Allen JC Jr, Lim ST, Soo KC, Ngeow J. Impact of subsidies on cancer genetic testing uptake in Singapore. J Med Genet. 2017 Apr; 54(4):254-259. doi:10.1136/jmedgenet-2016-104302 [Epub ahead of print].
Paul J, Soujon M, Wengner AM, Zitzmann-Kolbe S, Sturz A, Haike K, Keng Magdalene KH, Tan SH, Lange M, Tan SY, Mumberg D, Lim ST, Ziegelbauer K, Liu N. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT. Cancer cell. 2017 Jan 9;31(1):64-78. doi:10.1016/j.ccell.2016.12.003
Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJ, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase 2 study. Haematologica. 2017 Jan 25. doi:10.3324/haematol.2016.154377
Yeang SH, Chan A, Tan CW, Lim ST, Ng HJ. Incidence and Management of Toxicity Associated with L-Asparaginase in the Treatment of ALL and NK/TCell Lymphoma: an Observational Study. Asian Pac J Cancer Prev. 2016;17(7):3155-60.
Li Z, Xia Y, Feng LN, Chen JR, Li HM, Cui J, Cai QQ, Sim KS, Nairismägi ML, Laurensia Y, Meah WY, Liu WS, Guo YM, Chen LZ, Feng QS, Pang CP, Chen LJ, Chew SH, Ebstein RP, Foo JN, Liu J, Ha J, Khoo LP, Chin ST, Zeng YX, Aung T, Chowbay B, Diong CP, Zhang F, Liu YH, Tang T, Tao M, Quek R, Mohamad F, Tan SY, Teh BT, Ng SB, Chng WJ, Ong CK, Okada Y, Raychaudhuri S, Lim ST, Tan W, Peng RJ, Khor CC, Bei JX. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016 Sep;17(9):1240-7 doi:10.1016/S1470-2045(16)30148-6
Khor CC, Do T, Jia H, et al. Genome-wide association study identifies five new susceptibility loci for primary angle closure glaucoma. Nat Genet. 2016 Apr; 4.doi:10.1038/ng.3540
Tan RY, Met-Domestici M, Zhou K, Guzman AB, Lim ST, Soo KC, Feeley TW, Ngeow J. Using Quality Improve Methods And Time-Driven Activity-Based Costing to Improve Value-Based Cancer Care Delivery at a Cancer Genetic Clinic. J Oncol Pract. 2016 Mar; 12(3):e320-21.
Tang T, Chen Z, Praditsuktavorn P, Khoo LP, Ruan J, Lim ST, Tan D, Phipps C, Lee YS, Goh YT, Hwang W, Tao M, Quek R, Farid M, Furman RR, Leonard JP, Martin P. Role of Surveillance Imaging in Patient With Peripheral T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):117-21.
Seok Jin Kim, Dok Hyun Yoon, Arnaud Jaccard, Wee Joo Chng, Soon Thye Lim, Huangming Hong, Yong Park, Kian Meng Chang, Yoshinobu Maeda, Fumihiro Ishida, Dong-Yeop Shin, Jin Seok Kim, Seong Hyun Jeong, Deok-Hwan Yang, Jae-Cheol Jo, Gyeong-Won Lee, Chul Won Choi, Won-Sik Lee, Tsai-Yun Chen, Kiyeun Kim, Sin-Ho Jung, Tohru Murayama, Yasuhiro Oki, Ranjana Advani, Francesco d’Amore, Norbert Schmitz, Cheolwon Suh, Ritsuro Suzuki, Yok Lam Kwong, Tong-Yu Lin, and Won Seog Kim. A prognostic index for natural killer cell lymphoma in the contemporary era of nonanthracycline-based treatment: a multicenter, retrospective analysis. Lancet Oncology. 2016 Mar; 17(3):389-400.
Chua C, Raaj J, Pan S, Farid M, Lee JF, Ho ZC, Sairi A, Sittampalam K, Tao M, Tay K, Lim ST, Chin F, Teo M, Quek R. Brain metastasis in sarcoma: Does metastasectomy or aggressive multi-disciplinary treatment improve survival outcomes. Asia Pac J Clin Oncol. 2016 Mar; 12(1):e16-22.
Wang XJ, Tang T, Farid M, Quek R, Tao M, Lim ST, Wee HL, Chan A. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy. PLoS One. 2016 Feb 12;11(2):e0148901.